 | Review waiting, please be patient.
This may take 3 months or more, since drafts are reviewed in no specific order. There are 1,520 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
| Clinical data | |
|---|---|
| Other names | Hymantane; N-Adamant-2-ylhexamethyleneimine; N-(2-Adamantyl)hexamethyleneimine |
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C16H27N |
| Molar mass | 233.399 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Hemantane, or hymantane, also known as N-(2-adamantyl)hexamethyleneimine, is an experimental antiparkinsonian agent of the adamantane family that was never marketed.[1] It was developed and studied in Russia.[1]
It has been said to act as a low-affinity non-competitive NMDA receptor antagonist, selective MAO-B inhibitor, and to show various other actions and effects such as modulation of the dopaminergic and serotonergic systems in the striatum.[1][2] The drug has also theorized to be a sigma receptor agonist, which is said to likely be involved in its dopaminergic effects.[1] Analogues of hemantane, such as memantine and amantadine, share some of these actions, like NMDA receptor antagonism, sigma receptor agonism, and dopaminergic modulation.[1]
References
edit- ^ a b c d e Abaimov, D. A.; Kovalev, G. I. (2011). "Sigma receptors as a pharmacological target for neuroprotectors. New horizons of pharmacotherapy of Parkinson disease". Neurochemical Journal. 5 (2): 83–91. doi:10.1134/S1819712411010028. ISSN 1819-7124.
- ^ Fischler PV, Soyka M, Seifritz E, Mutschler J (2022). "Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review". Front Pharmacol. 13: 927703. doi:10.3389/fphar.2022.927703. PMC 9574013. PMID 36263121.
- ^ Val'dman EA (2000). "[Pharmacological activity of the new adamantane derivative--potential antiparkinson preparation during subchronic administration]". Eksp Klin Farmakol (in Russian). 63 (5): 3–6. PMID 11109514.
- ^ Andiarzhanova EA, Val'dman EA, Kudrin VS, Raevskiĭ KS, Voronina TA (2001). "[Effect of the new potential anti-Parkinson agent, hymantane, on levels of monoamines and their metabolites in rat striatum (a microdialysis study)]". Eksp Klin Farmakol (in Russian). 64 (6): 13–16. PMID 11871228.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |